ELEVATE-TN: a phase 3, multicentre, open-label study of acalabrutinib (Ab) combined with obinutuzumab (O) or Ab alone versus O plus chlorambucil (Clb) in patients (pts) with treatment-naive chronic lymphocytic leukaemia (TN-CLL)

被引：0

作者：

Munir, T. ^{[1
]}

Sharman, J. ^{[2
]}

Banerji, V. ^{[3
]}

Fogliatto, L. M. ^{[4
]}

Herishanu, Y. ^{[5
]}

Walewska, R. ^{[6
]}

Follows, G. ^{[7
]}

Karlsson, K. ^{[8
]}

Ghia, P. ^{[9
,10
,24
]}

Corbett, G. ^{[11
]}

Walker, P. ^{[12
,24
]}

Egyed, M. ^{[13
]}

Jurczak, W. ^{[14
]}

Salles, G. ^{[15
]}

Janssens, A. ^{[16
]}

Cymbalista, F. ^{[17
]}

Wierda, W. ^{[18
]}

Coutre, S. ^{[19
]}

Pagel, J. M. ^{[20
]}

Skarbnik, A. P. ^{[21
]}

Kamdar, M. ^{[22
]}

Woyach, J. A. ^{[23
]}

Izumi, R. ^{[24
]}

Munugalavadla, V. ^{[24
]}

Patel, P. ^{[24
]}

Wang, M. H. ^{[24
]}

Wong, S. ^{[24
]}

Byrd, J. C. ^{[23
]}

机构：

[1] St Jamess Inst Oncol, HMDS, Haematol, Leeds, W Yorkshire, England

[2] Willamette Valley Canc Inst & Res Ctr, Eugene, OR USA

[3] CancerCare Manitoba Fdn, Dept Internal Med, Biochem Med Genet, Winnipeg, MB, Canada

[4] Univ Fed Rio Grande Sul UFRS, Porto Alegre, RS, Brazil

[5] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel

[6] Royal Bournemouth Hosp, Bournemouth, Dorset, England

[7] Addenbrookes Hosp NHS Trust, Cambridge, England

[8] Skane Univ Hosp, Lund, Sweden

[9] Univ Vita Salute San Raffaele, Milan, Italy

[10] IRCCS Osped San Raffaele, Milan, Italy

[11] Tauranga Hosp, Tauranga, New Zealand

[12] Alfred Hlth Monash Univ, Melbourne, Vic, Australia

[13] Somogy Cty Mor Kaposi Gen Hosp, Kaposvar, Hungary

[14] Jagiellonian Univ Med Coll, Krakow, Poland

[15] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Pierre Benite, France

[16] Univ Hosp Leuven, Leuven, Belgium

[17] CHU Avicennes, Bobigny, France

[18] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[19] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[20] Swedish Canc Inst, Ctr Blood Disorders & Stem Cell Transplantat, Seattle, WA USA

[21] Novant Hlth, Div Lymphoma & Chron Lymphocyt Leukemia, Aurora, CO USA

[22] Univ Colorado, Canc Ctr, Aurora, CO USA

[23] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[24] Acerta Pharma, San Francisco, CA USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2020年 / 189卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BSH2020-OR

引用

页码：26 / 28

页数：3

共 33 条

[1] ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
Sharman, Jeff P.
Banerji, Versha
Fogliatto, Laura Maria
Herishanu, Yair
Munir, Talha
Walewska, Renata
Follows, George
Karlsson, Karin
Ghia, Paolo
Corbett, Gillian
Walker, Patricia
Egyed, Miklos
Jurczak, Wojciech
Salles, Gilles
Janssens, Ann
Cymbalista, Florence
Wierda, William G.
Coutre, Steven
Pagel, John M.
Skarbnik, Alan
Kamdar, Manali
Woyach, Jennifer
Izumi, Raquel
Munugalavadla, Veerendra
Patel, Priti
Wang, Min Hui
Wong, Sofia
Byrd, John C.
BLOOD, 2019, 134
[2] ELEVATE TN: Phase 3 Study of Acalabrutinib Combined With Obinutuzumab (O) or Alone vs O Plus Chlorambucil (Clb) in Patients With Treatment-Naive Chronic Lymphocytic Leukemia
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 17 - 18
[3] ELEVATE TN: Phase 3 Study of Acalabrutinib Combined With Obinutuzumab or Alone vs Obinutuzumab Plus Chlorambucil in Patients With Treatment-Naive Chronic Lymphocytic Leukemia
Awan, Farrukh T.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 2 - 4
[4] Acalabrutinib ± obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia: Elevate-TN four-year follow up.
Sharman, Jeff Porter
Egyed, Miklos
Jurczak, Wojciech
Skarbnik, Alan
Pagel, John M.
Kamdar, Manali K.
Munir, Talha
Corbett, Gillian
Fogliatto, Laura Maria
Herishanu, Yair
Banerji, Versha
Coutre, Steve E.
Walker, Patricia
Karlsson, Karin
Ghia, Paolo
Janssens, Ann
Wierda, William G.
Patel, Priti
Wang, Min Hui
Byrd, John C.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[5] PATIENT-REPORTED OUTCOMES FROM THE PHASE 3, RANDOMIZED STUDY OF ACALABRUTINIB WITH OR WITHOUT OBINUTUZUMAB VERSUS CHLORAMBUCIL PLUS OBINUTUZUMAB FOR TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA (ELEVATE-TN)
Walker, P.
Sharman, J. P.
Jurczak, W.
Munir, T.
Banerji, V
Coutre, S.
Woyach, J.
Salles, G.
Wierda, W. G.
Patel, P.
Wang, M. H.
Emeribe, U.
Flood, E.
Byrd, J. C.
Ghia, P.
VALUE IN HEALTH, 2021, 24 : S3 - S4
[6] Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial
Sharman, Jeff P.
Egyed, Miklos
Jurczak, Wojciech
Skarbnik, Alan
Pagel, John M.
Flinn, Ian W.
Kamdar, Manali
Munir, Talha
Walewska, Renata
Corbett, Gillian
Fogliatto, Laura Maria
Herishanu, Yair
Banerji, Versha
Coutre, Steven
Follows, George
Walker, Patricia
Karlsson, Karin
Ghia, Paolo
Janssens, Ann
Cymbalista, Florence
Woyach, Jennifer A.
Salles, Gilles
Wierda, William G.
Izumi, Raquel
Munugalavadla, Veerendra
Patel, Priti
Wang, Min Hui
Wong, Sofia
Byrd, John C.
LANCET, 2020, 395 (10232): : 1278 - 1291
[7] Acalabrutinib ± Obinutuzumab Vs Obinutuzumab plus Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN
Sharman, Jeff P.
Egyed, Miklos
Jurczak, Wojciech
Skarbnik, Alan
Patel, Krish
Flinn, Ian W.
Kamdar, Manali
Munir, Talha
Walewska, Renata
Hughes, Marie
Fogliatto, Laura Maria
Herishanu, Yair
Banerji, Versha
Follows, George
Walker, Patricia A.
Karlsson, Karin
Ghia, Paolo
Janssens, Ann
Cymbalista, Florence
Byrd, John C.
Ferrant, Emmanuelle
Ferrajoli, Alessandra
Wierda, William G.
Munugalavadla, Veerendra
Wachira, Catherine Wangui
Wun, Chuan-Chuan
Woyach, Jennifer A.
BLOOD, 2023, 142
[8] Acalabrutinib ± obinutuzumab vs obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia: ELEVATE-TN 4-year follow-up
Martens, U. M.
Sharman, J. P.
Egyed, M.
Jurczak, W.
Skarbnik, A.
Pagel, J. M.
Kamdar, M.
Munir, T.
Corbett, G.
Fogliatto, L. M.
Herishanu, Y.
Banerji, V
Coutre, S.
Walker, P.
Karlsson, K.
Ghia, P.
Janssens, A.
Wierda, W. G.
Patel, P.
Wang, M. H.
Byrd, J. C.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 106 - 106
[9] Acalabrutinib ± Obinutuzumab vs Obinutuzumab plus Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: ELEVATE-TN 4-Year Follow-up
Sharman, Jeff P.
Egyed, Miklos
Jurczak, Wojciech
Skarbnik, Alan
Pagel, John M.
Flinn, Ian W.
Kamdar, Manali
Munir, Talha
Walewska, Renata
Corbett, Gillian
Fogliatto, Laura Maria
Herishanu, Yair
Banerji, Versha
Coutre, Steven
Follows, George
Walker, Patricia
Karlsson, Karin
Ghia, Paolo
Janssens, Ann
Cymbalista, Florence
Woyach, Jennifer A.
Ferrant, Emmanuelle
Wierda, William G.
Munugalavadla, Veerendra
Patel, Priti
Wang, Min Hui
Byrd, John C.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S318 - S319
[10] Acalabrutinib ± Obinutuzumab vs Obinutuzumab plus Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 5-Year Follow-Up of ELEVATE-TN
Martens, Uwe
Sharman, Jeff
Egyed, Miklos
Jurczak, Wojciech
Skarbnik, Alan P.
Kamdar, Manali
Munir, Talha
Fogliatto, Laura Maria
Herishanu, Yair
Banerji, Versha
Follows, George
Walker, Patricia
Karlsson, Karin
Ghia, Paolo
Janssens, Ann
Ferrant, Emmanuelle
Munugalavadla, Veerendra
Yu, Ting
Wang, Min Hui
Woyach, Jennifer
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 166 - 167

← 1 2 3 4 →